Edition:
India

Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

14.60USD
17 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$14.60
Open
$14.74
Day's High
$14.79
Day's Low
$14.23
Volume
202,945
Avg. Vol
141,198
52-wk High
$23.01
52-wk Low
$12.69

Latest Key Developments (Source: Significant Developments)

Codexis Reports Q1 Non-GAAP Loss Per Share $0.05
Tuesday, 7 May 2019 

May 6 (Reuters) - Codexis Inc ::CODEXIS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.05.Q1 LOSS PER SHARE $0.09.Q1 REVENUE $15.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.FY2019 REVENUE VIEW $70.9 MILLION -- REFINITIV IBES DATA.  Full Article

Codexis Reports 2018 Fourth Quarter And Full Year Financial Results
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Codexis Inc ::CODEXIS REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.03.Q4 LOSS PER SHARE $0.01.Q4 REVENUE $16.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.7 MILLION.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.PRODUCT SALES ARE EXPECTED TO BE $26 MILLION TO $29 MILLION IN 2019.GROSS MARGIN ON PRODUCT SALES IS EXPECTED TO BE 48% TO 52% IN 2019.  Full Article

Codexis Announces Enzyme Supply Agreement With Kyorin Pharmaceutical For Overactive Bladder Drug Sold In Japan
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Codexis Inc ::CODEXIS ANNOUNCES ENZYME SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL FOR OVERACTIVE BLADDER DRUG SOLD IN JAPAN.CODEXIS INC - ANNOUNCES A MULTI-YEAR, EXCLUSIVE SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL CO., LTD..  Full Article

Codexis Q2 Loss Per Share $0.07
Thursday, 9 Aug 2018 

Codexis Inc ::CODEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.02.Q2 LOSS PER SHARE $0.07.Q2 REVENUE $13.5 MILLION VERSUS I/B/E/S VIEW $11.6 MILLION.SEES FY 2018 REVENUE $60 MILLION TO $63 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.PHASE 1A CLINICAL TRIAL FOR CDX-6114 INITIATED.SEES FY PRODUCT REVENUE TO BE $25 MILLION TO $28 MILLION.  Full Article

Codexis Announces Proposed Public Offering Of Common Stock
Friday, 6 Apr 2018 

April 6 (Reuters) - Codexis Inc ::CODEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Telemark Asset Management LLC reports 6.72 pct passive stake in Codexis ‍​as of Nov 10
Tuesday, 21 Nov 2017 

Nov 20 (Reuters) - Codexis Inc :Telemark Asset Management LLC reports 6.72 percent passive stake in Codexis Inc ‍​as of November 10 - SEC Filing.  Full Article

Codexis Q3 non-gaap loss per share $0.17
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Codexis Inc ::Codexis reports financial results for the third quarter of 2017.Q3 non-gaap loss per share $0.17.Q3 loss per share $0.21.Sees FY 2017 revenue $50 million to $53 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Codexis Inc - ‍total revenues for Q3 of 2017 were $10.0 million compared with $14.9 million for q3 of 2016​.Codexis Inc - ‍gross margin on product sales is expected to be between 40% and 43% for 2017​.  Full Article

Codexis Inc, Nestlé Health Science enter strategic collaboration​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Codexis Inc :Codexis Inc - ‍co, Nestlé Health Science enter strategic collaboration​.Codexis Inc - ‍Codexis receives an upfront payment of $14 million and potential milestones and royalties depending on product success for deal​.Codexis Inc - deal ‍includes an option for global development of CDX-6114 for PKU​.Codexis Inc - ‍Codexis will be responsible for clinical development costs for CDX-6114 up to and including Phase 1 in healthy volunteers​.Codexis - after ‍phase 1, Nestlé health science will have option to obtain exclusive global license to CDX-6114.Codexis - after ‍Phase 1, Nestlé health science will be responsible for all future development and commercialization of CDX-6114​.  Full Article